B7-H3×4-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8(+) tumor-infiltrating lymphocytes

Cancer immunotherapy with 4-1BB agonists has limited further clinical development because of dose-limiting toxicity. Here, we developed a bispecific antibody (bsAb; B7-H3×4-1BB), targeting human B7-H3 (hB7-H3) and mouse or human 4-1BB, to restrict the 4-1BB stimulation in tumors. B7-H3×m4-1BB elicit...

Descripción completa

Detalles Bibliográficos
Autores principales: You, Gihoon, Lee, Yangsoon, Kang, Yeon-Woo, Park, Han Wook, Park, Kyeongsu, Kim, Hyekang, Kim, Young-Min, Kim, Sora, Kim, Ji-Hae, Moon, Dain, Chung, Hyejin, Son, Wonjun, Jung, Ui-jung, Park, Eunyoung, Lee, Shinai, Son, Yong-Gyu, Eom, Jaehyun, Won, Jonghwa, Park, Yunji, Jung, Jaeho, Lee, Seung-Woo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7810375/
https://www.ncbi.nlm.nih.gov/pubmed/33523913
http://dx.doi.org/10.1126/sciadv.aax3160

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7810375/
https://www.ncbi.nlm.nih.gov/pubmed/33523913
http://dx.doi.org/10.1126/sciadv.aax3160

Ejemplares similares